VEGF Inhibitors do without venous thromboembolism not increase d-dimer levels in colorectal cancer patients: a retrospective non-inferiority analysis

3Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: If VEGF inhibitors contribute to an increase in D-dimer levels, they may adversely affect the diagnosis of venous thromboembolism (VTE). Consequently, this retrospective study examined the effects of VEGF inhibitors on D-dimer levels in colorectal cancer patients. Patients and Methods: A total of 104 colorectal cancer patients who received chemotherapy, were included in this study. To perform D-dimer analysis, patients were divided into two analysis targets: patients with VTE and without VTE. Statistical analysis included a natural logarithmic transformation of D-dimer data. Results: In the D-dimer analysis of non-VTE patients, the natural logarithm D-dimer mean difference was -0.186, with a 95% CI of -0.525 to 0.154. The upper limit of the 95%CI (0.154) did not exceed the non-inferiority margin (Δ) of 0.199, and therefore met the non-inferiority criteria. Conclusion: VEGF inhibitors don't contribute to increased D-dimer levels in colorectal cancer patients without VTE.

Cite

CITATION STYLE

APA

Toshima, H., Ikusue, T., Hisamatsu, A., Kobayashi, K., Ishida, H., & Shimada, K. (2019). VEGF Inhibitors do without venous thromboembolism not increase d-dimer levels in colorectal cancer patients: a retrospective non-inferiority analysis. In Vivo, 33(6), 2117–2123. https://doi.org/10.21873/invivo.11712

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free